PredicineATLAS™

600-gene cfDNA assay for TMB assessment and variant profiling

PredicineATLAS™ is the largest liquid biopsy assay for a complete cancer mutational landscape and accurate tumor mutation burden (TMB) calculation.  

  • Interrogates 600 cancer-related genes
  • Measures TMB and MSI status
  • Low input profiling 
  • Immuno-oncology applications

Sample types

Whole blood
Plasma
Urine
FFPE

Sample requirements

10ml whole blood
4ml plasma
40ml urine
10 FFPE slides

Turnaround time

10 days

Expanding the reach of cancer immunotherapy

Cancer immunotherapies have the potential to harness the immune system to treat cancer.  However, not all cancer patients respond to cancer immunotherapies.  TMB and MSI are emerging quantitative clinical biomarkers that can help predict response to certain cancer immunotherapies.  TMB-high and MSI-high patients have shown improved response rate to immunotherapies. 

Workflow

PredicineATLAS™ is a laboratory developed test. It is for research use only. 

PILOT PROGRAM

Our pilot program is available to select biopharma and academic partners to accelerate biomarker discoveries and biomarker-driven clinical studies.  To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and one of our dedicated team members will be in touch soon.

SEE OTHER TESTS